Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
BeOne Medicines
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine
Pharmacyclics LLC.
Novartis
Merck Sharp & Dohme LLC
Massachusetts General Hospital
Galapagos NV
Memorial Sloan Kettering Cancer Center
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Beth Israel Deaconess Medical Center
Janssen Research & Development, LLC
The First Affiliated Hospital of Xiamen University
Janssen Research & Development, LLC
University of Miami
Masonic Cancer Center, University of Minnesota
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
BeOne Medicines
Y-mAbs Therapeutics
National Institutes of Health Clinical Center (CC)
University of Chicago
Massachusetts General Hospital
AbbVie
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Dizal Pharmaceuticals
Chongqing Precision Biotech Co., Ltd
Hoffmann-La Roche
Genentech, Inc.
University of California, San Diego
Canadian Cancer Trials Group
St. Jude Children's Research Hospital
Genmab
Eli Lilly and Company
Lyell Immunopharma, Inc.
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Genmab
Cho Pharma Inc.
Genmab
Malaghan Institute of Medical Research
Baylor College of Medicine